CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for DURECT Corporation is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

DURECT Corporation
10260 Bubb Rd
Phone: (408) 777-1417p:408 777-1417 CUPERTINO, CA  95014-4166  United States Ticker: DRRXDRRX

Business Summary
Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board David R.Hoffmann 74 1/1/2019 12/27/2002
President, Chief Executive Officer and Director James E.Brown 62 6/1/1998 6/1/1998
Chief Financial Officer Michael H.Arenberg 49 10/15/2018 10/15/2018
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Absorbable Polymers International Corporation
DRRX
Southern BioSystems, Inc

General Information
Number of Employees: 88 (As of 12/31/2018)
Outstanding Shares: 192,362,179 (As of 10/30/2019)
Shareholders: 108
Stock Exchange: NASD
Federal Tax Id: 943297098
Fax Number: (408) 777-3577
Email Address: IR@durect.com


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 08, 2019